Page last updated: 2024-11-04

vorinostat and Muscular Dystrophy, Duchenne

vorinostat has been researched along with Muscular Dystrophy, Duchenne in 3 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)

Research Excerpts

ExcerptRelevanceReference
"The following parameters were evaluated: (i) number of ventricular arrhythmias in resting and stress conditions (restraint test) or after aconitine administration; (ii) cardiac excitability, conduction velocity, and refractoriness; (iii) expression and distribution of connexins (Cxs) and Na(v)1."3.76The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. ( Baruffi, S; Berni, R; Bocchi, L; Capogrossi, MC; Colussi, C; Delucchi, F; Gaetano, C; Macchi, E; Mai, A; Musso, E; Quaini, F; Rosati, J; Rossi, S; Rotili, D; Savi, M; Spallotta, F; Stilli, D; Straino, S; Vitale, S, 2010)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Colussi, C3
Berni, R2
Rosati, J2
Straino, S3
Vitale, S1
Spallotta, F3
Baruffi, S1
Bocchi, L1
Delucchi, F1
Rossi, S2
Savi, M1
Rotili, D2
Quaini, F1
Macchi, E2
Stilli, D2
Musso, E2
Mai, A3
Gaetano, C3
Capogrossi, MC3
Banfi, C1
Brioschi, M1
Tremoli, E1
Sbardella, G1
Castellano, S1
Chimenti, C1
Frustaci, A1
Nebbioso, A1
Altucci, L1

Other Studies

3 other studies available for vorinostat and Muscular Dystrophy, Duchenne

ArticleYear
The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice.
    Cardiovascular research, 2010, Jul-01, Volume: 87, Issue:1

    Topics: Aconitine; Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Connexins; Dise

2010
Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment.
    Proteomics. Clinical applications, 2010, Volume: 4, Issue:1

    Topics: Amino Acid Sequence; Animals; Blood Proteins; Dose-Response Relationship, Drug; Gene Expression Regu

2010
Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Feb-15, Volume: 108, Issue:7

    Topics: Acetylation; Anacardic Acids; Animals; Cardiomyopathies; Connexin 43; Gap Junctions; Histone Acetylt

2011